Steve Duffy, Author at Endocrinology Advisor - Page 2

Steve Duffy

All articles by Steve Duffy


Dulaglutide Assessed in T2D Patients With Chronic Kidney Disease

In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0.75mg (N=190) once-weekly, or insulin glargine daily (N=194), all in combination with insulin lispro, for 52 weeks. HbA1c at 26 weeks with a 0.4% non-inferiority margin was designated as the primary outcome, while secondary outcomes included eGFR and urine albumin-to-creatinine ratio.

Next post in Cardiovascular and Metabolic Disorders